Aurora Cannabis this week became the first main Canadian firm to sell edibles and vapes for medical use, a small base that nevertheless helps shore up margins and paves the way for gross sales in the much larger European pharmaceutical market.
Medical marijuana has been legal in Canada since 2001, and leisure use since October last year, however, derivatives – products from hashish extracts, like edibles – were solely authorized for sales this week for each medical and recreational use.
Aurora representative Cam Battley acknowledged this was a consideration in boosting its medical menu.
Canada’s second-largest marijuana producer added gummies, mints, and vapes to its medical menu Monday. Aurora refused to offer the value of medical sales thus far; however, it stated it ought to replenish gummies supplies on its website and noticed an uptick in patient registrations.
Aurora, like its competitors, will even sell leisure edibles, which have shipped, however, should make their way to stores shelves by government-managed wholesalers in most provinces. In contrast, corporations can ship medical marijuana products to registered sufferers now.
Big Canadian provinces like Ontario, Quebec, and Alberta will not start sales until not less than January.
Of the 51 corporations that Health Canada permits to supply derivatives for leisure use, 47 can also sell them in the medical market; however, few are doing so now.
A spokesperson for No. 4 producer Aphria Inc stated it would add three vape products, particularly for sufferers in January, as a part of its medical brand. Canada’s different leading cannabis corporations, Canopy Growth Corp and Tilray, mentioned they’re specializing in existing medical products; however, that would change in the future.